In a recent subgroup analysis study by Dinardo et al. [52], it was discovered that among AML patients receiving venetoclax-based therapies, the strongest molecular associations with response were found to be present in patients with mutations in genes such as IDH1, IDH2, NPM1, and DNMT3A. The gene discussed is IDH2; the disease is acute myeloid leukemia.